222 related articles for article (PubMed ID: 15550932)
1. The effect of etanercept on Graves' ophthalmopathy: a pilot study.
Paridaens D; van den Bosch WA; van der Loos TL; Krenning EP; van Hagen PM
Eye (Lond); 2005 Dec; 19(12):1286-9. PubMed ID: 15550932
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
3. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study.
Matteson EL; Choi HK; Poe DS; Wise C; Lowe VJ; McDonald TJ; Rahman MU
Arthritis Rheum; 2005 Jun; 53(3):337-42. PubMed ID: 15934127
[TBL] [Abstract][Full Text] [Related]
4. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept.
Baraliakos X; Davis J; Tsuji W; Braun J
Arthritis Rheum; 2005 Apr; 52(4):1216-23. PubMed ID: 15818694
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients.
Tobinick E; Davoodifar S
Curr Med Res Opin; 2004 Jul; 20(7):1075-85. PubMed ID: 15265252
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
Madhusudan S; Foster M; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Talbot DC; Ganesan TS; Harris AL
Clin Cancer Res; 2004 Oct; 10(19):6528-34. PubMed ID: 15475440
[TBL] [Abstract][Full Text] [Related]
9. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
de Vlam K; Lories RJ
Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
Bliddal H; Terslev L; Qvistgaard E; Konig M; Holm CC; Rogind H; Boesen M; Danneskiold-Samsøe B; Torp-Pedersen S
Scand J Rheumatol; 2006; 35(5):341-5. PubMed ID: 17062431
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.
Haraoui B; Keystone EC; Thorne JC; Pope JE; Chen I; Asare CG; Leff JA
J Rheumatol; 2004 Dec; 31(12):2356-9. PubMed ID: 15570634
[TBL] [Abstract][Full Text] [Related]
14. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus.
Martínez-Abundis E; Reynoso-von Drateln C; Hernández-Salazar E; González-Ortiz M
Arch Dermatol Res; 2007 Nov; 299(9):461-5. PubMed ID: 17726611
[TBL] [Abstract][Full Text] [Related]
15. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
16. Etanercept: effective in the management of hidradenitis suppurativa.
Cusack C; Buckley C
Br J Dermatol; 2006 Apr; 154(4):726-9. PubMed ID: 16536817
[TBL] [Abstract][Full Text] [Related]
17. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
18. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
Wallenius M; Rødevand E; Skomsvoll JF
Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1664-6. PubMed ID: 15976836
[TBL] [Abstract][Full Text] [Related]
19. Etanercept in the treatment of palmoplantar pustulosis.
Bissonnette R; Poulin Y; Bolduc C; Maari C; Provost N; Syrotuik J; Poulin-Costello CM; Nigen S
J Drugs Dermatol; 2008 Oct; 7(10):940-6. PubMed ID: 19112757
[TBL] [Abstract][Full Text] [Related]
20. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W
Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
